IRAKLIA Trial Validates Subcutaneous Isatuximab in Multiple Myeloma

Sikander Ailawadhi, MD, of the Mayo Clinic Florida in Jacksonville, discusses the clinical significance and primary outcomes of the IRAKLIA trial (NCT05405166), a study designed to refine the administration of isatuximab (Sarclisa) for patients with relapsed or refractory multiple myeloma. The current therapeutic standard involving isatuximab, specifically the combination of isatuximab, pomalidomide (Pomalyst), and dexamethasone (Isa-Pd), is FDA-approved as an intravenous (IV) infusion. However, IV administration is often associated with a significant treatment burden, requiring several hours for the initial dose and remaining a multi-hour commitment even after subsequent dose acceleration.

Trial Design and Methodology

The IRAKLIA trial was structured as a randomized, head-to-head comparison to evaluate a more efficient delivery method: a subcutaneous (SC) formulation administered via an on-body injector (OBI). The study compared the standard IV Isa-Pd regimen against the investigational SC Isa-Pd arm to determine if the subcutaneous delivery could match the established standard in efficacy, safety, and pharmacokinetics.

Primary Objectives and Key Findings

The trial was built around two primary objectives, both of which were successfully met. The analysis confirmed that subcutaneous isatuximab with the OBI was non-inferior to the intravenous version. Ailawadhi notes that both the clinical benefit and the safety profiles were remarkably similar between the two arms. Importantly, no new safety signals or concerns were identified with the subcutaneous delivery, providing strong reassurance for its clinical use. The second objective focused on drug levels in the blood at the end of six treatment cycles. The study demonstrated that the SC formulation achieved drug concentrations similar to those produced by the standard IV drug, ensuring that the change in delivery method did not compromise the systemic exposure of the medication.

Implications for Patient Care

The success of the IRAKLIA trial suggests a forthcoming shift in the management of relapsed or refractory multiple myeloma. By proving that the subcutaneous OBI method is non-inferior to the IV standard, the study supports a transition toward a more patient-centric delivery model. This approach maintains the full therapeutic potency of the Isa-Pd regimen while significantly reducing administration time and alleviating the logistical constraints placed on both patients and infusion centers.